Inflammatix is developing novel molecular diagnostics for acute infections and sepsis that work by ‘reading’ the immune system. Founded by Jonathan Romanowsky, Purvesh Khatri, and Tim Sweeney in 2016, Inflammatix is backed by investors that include StartX (Stanford-StartX Fund), Khosla Ventures, DARPA, Northpond Ventures, and Think.Health and is headquartered in Burlingame, California.